1. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure
by Benjamin W. Van Tassell, Justin Canada, Salvatore Carbone, Cory Trankle, Leo Buckley, Claudia Oddi Erdle, Nayef A. Abouzaki, Dave Dixon, Dinesh Kadariya, Sanah Christopher, Aaron Schatz, Jessica Regan, Michele Viscusi, Marco Del Buono, Ryan Melchior, Pranav Mankad, Juan Lu, Robin Sculthorpe, Giuseppe Biondi-Zoccai, Edward Lesnefsky, Ross Arena, and Antonio Abbate
Circ Heart Fail
Volume 10(11):e004373
November 15, 2017
Copyright © American Heart Association, Inc. All rights reserved.

2. Screening and enrollment of patients.
Screening and enrollment of patients. CPX indicates cardiopulmonary exercise test; and CRP, C-reactive protein.
Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373
Copyright © American Heart Association, Inc. All rights reserved.

3. Effects of treatment on peak volume of oxygen consumption (VO2) and minute ventilation-carbon dioxide production slope (VE/VCO2) slope.
Effects of treatment on peak volume of oxygen consumption (VO2) and minute ventilation-carbon dioxide production slope (VE/VCO2) slope. Columns represent median values (vertical bars represent interquartile ranges).
Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373
Copyright © American Heart Association, Inc. All rights reserved.

4. Effects of treatment on plasma C-reactive protein (CRP) levels.
Effects of treatment on plasma C-reactive protein (CRP) levels. Columns represent median values (vertical bars represent interquartile ranges) using a logarithmic scale.
Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373
Copyright © American Heart Association, Inc. All rights reserved.

5. Effects of treatment on left ventricular volume and systolic and diastolic function.
Effects of treatment on left ventricular volume and systolic and diastolic function. Columns represent median values (vertical bars represent interquartile ranges). E indicates early mitral pulsed-wave Doppler flow velocity; E′, early mitral annulus tissue pulsed-wave Doppler velocity; and LVEF, left ventricular ejection fraction.
Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373
Copyright © American Heart Association, Inc. All rights reserved.

6. Effects of treatment on quality-of-life measures.
Effects of treatment on quality-of-life measures. Columns represent median values (vertical bars represent interquartile ranges). DASI indicates Duke Activity Status Index; and MLWHF, Minnesota Living With Heart Failure Questionnaire.
Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373
Copyright © American Heart Association, Inc. All rights reserved.

7. Effects of treatment on survival free of hospital readmission for heart failure (HF).
Effects of treatment on survival free of hospital readmission for heart failure (HF). The incidence of death or readmission for HF at 24 wk was 30% in the placebo group, 31% in the group treated with anakinra for 2 wk, and 6% in the group treated with anakinra 12 wk (log-rank P test P=0.10).
Benjamin W. Van Tassell et al. Circ Heart Fail. 2017;10:e004373
Copyright © American Heart Association, Inc. All rights reserved.